{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:40Z","timestamp":1791229540577,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD\/NASH therapy, however, there is currently no specific drug therapy for NAFLD\/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD\/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD\/NASH in Japan.<\/jats:p>","DOI":"10.1007\/s00535-021-01796-x","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T03:04:47Z","timestamp":1631847887000},"page":"951-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":232,"title":["Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020"],"prefix":"10.1007","volume":"56","author":[{"given":"Katsutoshi","family":"Tokushige","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ikejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoh","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kogiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooru","family":"Shimosegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"1796_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"1796_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547\u201355.","journal-title":"Gastroenterology"},{"key":"1796_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69:896\u2013904.","journal-title":"J Hepatol"},{"key":"1796_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00535-015-1050-7","volume":"50","author":"S Watanabe","year":"2015","unstructured":"Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364\u201377.","journal-title":"J Gastroenterol"},{"key":"1796_CR5","first-page":"1388","volume":"64","author":"EASL-EASD-EASO","year":"2016","unstructured":"EASL-EASD-EASO. Clinical Practice Guidelines for the management of non- alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u20131402.","journal-title":"J Hepatol"},{"key":"1796_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","volume":"47","author":"Y Eguchi","year":"2012","unstructured":"Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586\u201395.","journal-title":"J Gastroenterol"},{"key":"1796_CR7","doi-asserted-by":"publisher","first-page":"e76161","DOI":"10.1371\/journal.pone.0076161","volume":"8","author":"M Hashiba","year":"2013","unstructured":"Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS ONE. 2013;8:e76161.","journal-title":"PLoS ONE"},{"key":"1796_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148\u201355.","journal-title":"J Hepatol"},{"key":"1796_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"issue":"2","key":"1796_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389\u201397.e10.","journal-title":"Gastroenterology."},{"key":"1796_CR11","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365.","journal-title":"Hepatology"},{"key":"1796_CR12","doi-asserted-by":"crossref","unstructured":"Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. J Gastroenterol Hepatol. In press. 2020.","DOI":"10.1111\/jgh.14989"},{"key":"1796_CR13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264-1281.e4.","journal-title":"Gastroenterology"},{"key":"1796_CR14","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","volume":"158","author":"R Loomba","year":"2020","unstructured":"Loomba R, Lim JK, Patton H, El-Serag HB. aga clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology. 2020;158:1822\u201330.","journal-title":"Gastroenterology"},{"key":"1796_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ajg.2011.327","volume":"107","author":"Y Kawamura","year":"2012","unstructured":"Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253\u201361.","journal-title":"Am J Gastroenterol"},{"key":"1796_CR16","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.23527","volume":"51","author":"MS Ascha","year":"2010","unstructured":"Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972\u20138.","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"1796_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/jgh.12239","volume":"28","author":"K Tokushige","year":"2013","unstructured":"Tokushige K, Hashimoto E, Kodama K. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. J Gastroenterol Hepatol. 2013;28(Suppl 4):88\u201392.","journal-title":"J Gastroenterol Hepatol"},{"key":"1796_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","volume":"65","author":"SM Francque","year":"2016","unstructured":"Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425\u201343.","journal-title":"J Hepatol"},{"key":"1796_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","volume":"151","author":"DH Sinn","year":"2016","unstructured":"Sinn DH, Cho SJ, Gu S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology. 2016;151:481-488.e1.","journal-title":"Gastroenterology"},{"key":"1796_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589\u2013600.","journal-title":"J Hepatol"},{"key":"1796_CR21","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.12688\/f1000research.12417.1","volume":"6","author":"U Summart","year":"2017","unstructured":"Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study. F1000Res. 2017;6:1630.","journal-title":"F1000Res"},{"key":"1796_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1796_CR23","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851\u201364.","journal-title":"Gastroenterology"},{"key":"1796_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175\u201383.","journal-title":"JAMA"},{"key":"1796_CR25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1440-1746.2007.05001.x","volume":"22","author":"S Chitturi","year":"2007","unstructured":"Chitturi S, Farrell GC, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778\u201387.","journal-title":"J Gastroenterol Hepatol"},{"key":"1796_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3748\/wjg.v18.i13.1508","volume":"18","author":"M Hamaguchi","year":"2012","unstructured":"Hamaguchi M, Takeda N, Kojima T, et al. Identification of individuals with non- alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;18:1508\u201316.","journal-title":"World J Gastroenterol"},{"key":"1796_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"1796_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00535-010-0311-8","volume":"46","author":"E Hashimoto","year":"2011","unstructured":"Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol. 2011;46(Suppl 1):63\u20139.","journal-title":"J Gastroenterol"},{"key":"1796_CR29","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nature04634","volume":"440","author":"N Houstis","year":"2006","unstructured":"Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440:944\u20138.","journal-title":"Nature"},{"key":"1796_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/hep.22399","volume":"48","author":"JJ Maher","year":"2008","unstructured":"Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670\u20138.","journal-title":"Hepatology"},{"key":"1796_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","volume":"52","author":"AP Rolo","year":"2012","unstructured":"Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59\u201369.","journal-title":"Free Radic Biol Med"},{"key":"1796_CR32","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461\u20135.","journal-title":"Nat Genet"},{"key":"1796_CR33","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/hep.23823","volume":"52","author":"L Valenti","year":"2010","unstructured":"Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain- containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52:1274\u201380.","journal-title":"Hepatology"},{"key":"1796_CR34","doi-asserted-by":"publisher","first-page":"e38322","DOI":"10.1371\/journal.pone.0038322","volume":"7","author":"T Kawaguchi","year":"2012","unstructured":"Kawaguchi T, Sumida Y, Umemura A, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS ONE. 2012;7:e38322.","journal-title":"PLoS ONE"},{"key":"1796_CR35","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","volume":"285","author":"S He","year":"2010","unstructured":"He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706\u201315.","journal-title":"J Biol Chem"},{"key":"1796_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.bbalip.2013.12.006","volume":"1841","author":"P Pingitore","year":"2014","unstructured":"Pingitore P, Pirazzi C, Mancina RM, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta. 2014;1841:574\u201380.","journal-title":"Biochim Biophys Acta"},{"key":"1796_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/hep.29273","volume":"66","author":"S BasuRay","year":"2017","unstructured":"BasuRay S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017;66:1111\u201324.","journal-title":"Hepatology"},{"key":"1796_CR38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/hepr.12840","volume":"47","author":"Y Seko","year":"2017","unstructured":"Seko Y, Sumida Y, Tanaka S, et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis\/fibrosis progression. Hepatol Res. 2017;47:1083\u201392.","journal-title":"Hepatol Res"},{"key":"1796_CR39","doi-asserted-by":"publisher","first-page":"e0185490","DOI":"10.1371\/journal.pone.0185490","volume":"13","author":"T Kawaguchi","year":"2018","unstructured":"Kawaguchi T, Shima T, Mizuno M, et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS ONE. 2018;13:e0185490.","journal-title":"PLoS ONE"},{"key":"1796_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352\u20136.","journal-title":"Nat Genet"},{"key":"1796_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/hep.27490","volume":"61","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61:506\u201314.","journal-title":"Hepatology"},{"issue":"150","key":"1796_CR42","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"05","author":"RM Mancina","year":"2016","unstructured":"Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;05(150):1219-30.e6.","journal-title":"Gastroenterology"},{"key":"1796_CR43","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","volume":"7","author":"B Donati","year":"2017","unstructured":"Donati B, Dongiovanni P, Romeo S, et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017;7:4492.","journal-title":"Sci Rep"},{"key":"1796_CR44","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764\u201375.","journal-title":"Hepatology"},{"key":"1796_CR45","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25:1054-62.e5.","journal-title":"Cell Metab"},{"key":"1796_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179\u201385.","journal-title":"Nature"},{"key":"1796_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","volume":"66","author":"BK Koo","year":"2017","unstructured":"Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non- alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66:123\u201331.","journal-title":"J Hepatol"},{"key":"1796_CR48","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898\u2013906.","journal-title":"Gastroenterology"},{"key":"1796_CR49","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/hep.21346","volume":"44","author":"RB Merriman","year":"2006","unstructured":"Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology. 2006;44:874\u201380.","journal-title":"Hepatology"},{"key":"1796_CR50","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1007\/s00535-011-0436-4","volume":"46","author":"M Yoneda","year":"2011","unstructured":"Yoneda M, Fujii H, Sumida Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300\u20136.","journal-title":"J Gastroenterol"},{"key":"1796_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/jgh.14448","volume":"34","author":"T Ito","year":"2019","unstructured":"Ito T, Ishigami M, Ishizu Y, et al. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019;34:207\u201314.","journal-title":"J Gastroenterol Hepatol"},{"key":"1796_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-230X-12-2","volume":"12","author":"Y Sumida","year":"2012","unstructured":"Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.","journal-title":"BMC Gastroenterol"},{"key":"1796_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12072-014-9605-x","volume":"9","author":"Y Kawamura","year":"2015","unstructured":"Kawamura Y, Ikeda K, Arase Y, et al. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. Hepatol Int. 2015;9:269\u201377.","journal-title":"Hepatol Int"},{"key":"1796_CR54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112:740\u201351.","journal-title":"Am J Gastroenterol"},{"key":"1796_CR55","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00535-018-1474-y","volume":"53","author":"H Ishiba","year":"2018","unstructured":"Ishiba H, Sumida Y, Tanaka S, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol. 2018;53:1216\u201324.","journal-title":"J Gastroenterol"},{"key":"1796_CR56","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/hep.25756","volume":"56","author":"H Ochi","year":"2012","unstructured":"Ochi H, Hirooka M, Koizumi Y, et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology. 2012;56:1271\u20138.","journal-title":"Hepatology"},{"key":"1796_CR57","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/hep.28394","volume":"63","author":"C Cassinotto","year":"2016","unstructured":"Cassinotto C, Boursier J, de L\u00e9dinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016;63:1817\u201327.","journal-title":"Hepatology"},{"key":"1796_CR58","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/gut.2007.126417","volume":"56","author":"M Yoneda","year":"2007","unstructured":"Yoneda M, Fujita K, Inamori M, et al. Transient elastography in patients with non- alcoholic fatty liver disease (NAFLD). Gut. 2007;56:1330\u20131.","journal-title":"Gut"},{"key":"1796_CR59","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150:626-37.e7.","journal-title":"Gastroenterology"},{"key":"1796_CR60","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486\u2013501.","journal-title":"Hepatology"},{"key":"1796_CR61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","volume":"56","author":"C Thoma","year":"2012","unstructured":"Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non- alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255\u201366.","journal-title":"J Hepatol"},{"key":"1796_CR62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121\u20139.","journal-title":"Hepatology"},{"key":"1796_CR63","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.2337\/dc10-0856","volume":"33","author":"M Lazo","year":"2010","unstructured":"Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33:2156\u201363.","journal-title":"Diabetes Care"},{"key":"1796_CR64","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","volume":"55","author":"G Musso","year":"2012","unstructured":"Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885\u2013904.","journal-title":"Diabetologia"},{"key":"1796_CR65","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-378.e5.","journal-title":"Gastroenterology"},{"key":"1796_CR66","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","volume":"59","author":"MC Ryan","year":"2013","unstructured":"Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138\u201343.","journal-title":"J Hepatol"},{"key":"1796_CR67","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829\u201346.","journal-title":"J Hepatol"},{"key":"1796_CR68","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/MEG.0000000000000776","volume":"29","author":"K Wijarnpreecha","year":"2017","unstructured":"Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:e8\u201312.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1796_CR69","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.cgh.2013.04.039","volume":"11","author":"F Bravi","year":"2013","unstructured":"Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1413-21.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1796_CR70","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/hep.23129","volume":"50","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105\u201312.","journal-title":"Hepatology"},{"key":"1796_CR71","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/oby.2009.274","volume":"18","author":"GJ van der Heijden","year":"2010","unstructured":"van der Heijden GJ, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring). 2010;18:384\u201390.","journal-title":"Obesity (Silver Spring)"},{"key":"1796_CR72","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/hep.27544","volume":"61","author":"S Oh","year":"2015","unstructured":"Oh S, Shida T, Yamagishi K, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology. 2015;61:1205\u201315.","journal-title":"Hepatology"},{"key":"1796_CR73","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","volume":"2","author":"AJ Sanyal","year":"2004","unstructured":"Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107\u201315.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1796_CR74","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385.","journal-title":"N Engl J Med"},{"key":"1796_CR75","doi-asserted-by":"publisher","first-page":"e4529","DOI":"10.1097\/MD.0000000000004529","volume":"95","author":"R Sawangjit","year":"2016","unstructured":"Sawangjit R, Chongmelaxme B, Phisalprapa P, et al. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016;95:e4529.","journal-title":"Medicine (Baltimore)"},{"key":"1796_CR76","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633\u201340.","journal-title":"JAMA Intern Med"},{"key":"1796_CR77","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","volume":"31","author":"G Svegliati-Baroni","year":"2011","unstructured":"Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31:1285\u201397.","journal-title":"Liver Int"},{"key":"1796_CR78","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"1796_CR79","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64:399\u2013408.","journal-title":"J Hepatol"},{"key":"1796_CR80","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/hepr.12351","volume":"45","author":"Y Eguchi","year":"2015","unstructured":"Eguchi Y, Kitajima Y, Hyogo H, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45:269\u201378.","journal-title":"Hepatol Res"},{"key":"1796_CR81","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","volume":"65","author":"J Cui","year":"2016","unstructured":"Cui J, Philo L, Nguyen P, et al. Sitagliptin vs placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016;65:369\u201376.","journal-title":"J Hepatol"},{"key":"1796_CR82","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","volume":"10","author":"M Kawakubo","year":"2020","unstructured":"Kawakubo M, Tanaka M, Ochi K, et al. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Sci Rep. 2020;10:983.","journal-title":"Sci Rep"},{"key":"1796_CR83","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00535-017-1364-8","volume":"53","author":"Y Seko","year":"2018","unstructured":"Seko Y, Sumida Y, Sasaki K, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018;53:140\u201351.","journal-title":"J Gastroenterol"},{"key":"1796_CR84","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.diabet.2018.08.001","volume":"44","author":"HS Bajaj","year":"2018","unstructured":"Bajaj HS, Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R. SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes. Diabetes Metab. 2018;44:493\u20139.","journal-title":"Diabetes Metab"},{"key":"1796_CR85","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.2169\/internalmedicine.4398-19","volume":"59","author":"N Akuta","year":"2020","unstructured":"Akuta N, Kawamura Y, Fujiyama S, et al. SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology. Intern Med. 2020;59:1931\u20137.","journal-title":"Intern Med"},{"key":"1796_CR86","doi-asserted-by":"publisher","first-page":"e013389","DOI":"10.1161\/JAHA.119.013389","volume":"8","author":"CSP Lam","year":"2019","unstructured":"Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019;8:e013389.","journal-title":"J Am Heart Assoc"},{"key":"1796_CR87","doi-asserted-by":"publisher","first-page":"e00163","DOI":"10.1002\/edm2.163","volume":"3","author":"X Lv","year":"2020","unstructured":"Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): a systematic review. Endocrinol Diabetes Metab. 2020;3:e00163.","journal-title":"Endocrinol Diabetes Metab"},{"key":"1796_CR88","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hep4.1019","volume":"1","author":"N Akuta","year":"2017","unstructured":"Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1:46\u201352.","journal-title":"Hepatol Commun"},{"key":"1796_CR89","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705\u201312.","journal-title":"J Hepatol"},{"key":"1796_CR90","doi-asserted-by":"publisher","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","volume":"21","author":"K Kargiotis","year":"2015","unstructured":"Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21:7860\u20138.","journal-title":"World J Gastroenterol"},{"key":"1796_CR91","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/hep.24558","volume":"54","author":"DM Torres","year":"2011","unstructured":"Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology. 2011;54:1631\u20139.","journal-title":"Hepatology"},{"key":"1796_CR92","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/liv.12611","volume":"35","author":"GB Goh","year":"2015","unstructured":"Goh GB, Pagadala MR, Dasarathy J, et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 2015;35:979\u201385.","journal-title":"Liver Int"},{"key":"1796_CR93","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","volume":"41","author":"H Hyogo","year":"2011","unstructured":"Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2011;41:1057\u201365.","journal-title":"Hepatol Res"},{"key":"1796_CR94","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.20092","volume":"39","author":"KD Lindor","year":"2004","unstructured":"Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770\u20138.","journal-title":"Hepatology"},{"key":"1796_CR95","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.23727","volume":"52","author":"UF Leuschner","year":"2010","unstructured":"Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472\u20139.","journal-title":"Hepatology"},{"key":"1796_CR96","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.23623","volume":"52","author":"G Musso","year":"2010","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79\u2013104.","journal-title":"Hepatology"},{"key":"1796_CR97","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u201365.","journal-title":"Lancet"},{"key":"1796_CR98","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147-1159.e5.","journal-title":"Gastroenterology"},{"key":"1796_CR99","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/hep.29724","volume":"68","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361\u201371.","journal-title":"Hepatology"},{"key":"1796_CR100","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","volume":"67","author":"R Loomba","year":"2018","unstructured":"Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67:549\u201359.","journal-title":"Hepatology"},{"key":"1796_CR101","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","volume":"67","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67:1754\u201367.","journal-title":"Hepatology"},{"key":"1796_CR102","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1016\/S0140-6736(18)32165-2","volume":"392","author":"VWS Wong","year":"2019","unstructured":"Wong VWS, Adams LA. Fibroblast growth factor 21 for non-alcoholic steatohepatitis. Lancet. 2019;392:2658\u201360.","journal-title":"Lancet"},{"key":"1796_CR103","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","volume":"12","author":"R Safadi","year":"2014","unstructured":"Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085-91.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1796_CR104","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36\u201343.","journal-title":"Atherosclerosis"},{"key":"1796_CR105","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/apt.13816","volume":"44","author":"SA Harrison","year":"2016","unstructured":"Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther. 2016;44:1183\u201398.","journal-title":"Aliment Pharmacol Ther"},{"key":"1796_CR106","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/hep.29246","volume":"66","author":"K Stiede","year":"2017","unstructured":"Stiede K, Miao W, Blanchette HS, et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study. Hepatology. 2017;66:324\u201334.","journal-title":"Hepatology"},{"issue":"2","key":"1796_CR107","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2020","unstructured":"Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH. Hepatology. 2020;73(2):625\u201343.","journal-title":"Hepatology."},{"key":"1796_CR108","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/hepr.13425","volume":"49","author":"Y Sumida","year":"2019","unstructured":"Sumida Y, Okanoue T, Nakajima A, (JSG-NAFLD) JSGoN. Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res. 2019;49:1256\u201362.","journal-title":"Hepatol Res"},{"key":"1796_CR109","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2337\/dc12-1235","volume":"36","author":"K Kodama","year":"2013","unstructured":"Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36:1789\u201396.","journal-title":"Diabetes Care"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-021-01796-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T14:09:03Z","timestamp":1634825343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-021-01796-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":109,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1007\/s00535-021-01796-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"14 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the authors, the spouse, partner or immediate relatives of authors, have received individually any income, honoraria, or any other types of remuneration\u2014MSD, Otsuka Pharmaceutical, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Lundbeck Japan, AbbVie, Gilead Sciences, Sumitomo Dainippon Pharma, Novo Nordisk, EA Pharma, Astellas Pharma, Mylan, Mochida Pharmaceutical, Kowa Company, Tsumura & CO., and (2) those from which the academic institutions of the authors received support (commercial\/academic cooperation)\u2014EA Pharma, Astellas Pharma, Eisai, MSD, Otsuka Pharmaceutical, Suntory Global Innovation Center, Shionogi & Co., Daiichi Sankyo, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Bayer Yakuhin, Bristol-Myers Squibb, Mochida Pharmaceutical, Yakult Honsha, AbbVie, Gilead Sciences, Gadelius Medical, Novartis Pharma, Eli Lilly Japan, Mylan N.V., Century Medical, Sogo Rinsho Medefi, Nissan Chemical, Fujirebio. Kowa, Kyokuto Pharmaceutical Industrial. Biofermin Pharmaceutical, and (3) those from which the authors have received individually endowed chair\u2014NichiNichi Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}